Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79038 | 0.94 | MEN1 (0.88) | ADRA1ADRD3HTR2AHRH1OPRK1 | |
| SCHEMBL10558316 | 0.89 | ADRA1A (0.80) | ADRA1ADRD3HTR2AHRH1OPRK1 | |
| SCHEMBL10683725 | 0.86 | ADRA1A (0.76) | ADRA1ADRD3HTR2AHRH1OPRK1 | |
| SCHEMBL10676648 | 0.85 | ADRA1A (0.73) | ADRA1ADRD3HTR2AHRH1OPRK1 | |
| Lidoflazine SCHEMBL28086565 | 0.84 | ADRA1A (0.71) | ADRA1ADRD3HTR2AHRH1OPRK1 | |
| SCHEMBL4500966 | 0.84 | MEN1 (0.72) | ADRA1ADRD3HTR2AHRH1OPRK1 | |
| Hydrochloric Acid SCHEMBL10675752 | 0.84 | ADRA1A (0.71) | ADRA1ADRD3HTR2AHRH1OPRK1 | |
| SCHEMBL10554577 | 0.83 | HTR2A (0.71) | ADRA1ADRD3HTR2AHRH1OPRK1 | |
| SCHEMBL10676097 | 0.83 | ADRA1A (0.70) | ADRA1ADRD3HTR2AHRH1OPRK1 | |
| Cadaverine Tartrate SCHEMBL10675929 | 0.81 | ADRA1A (0.68) | ADRA1ADRD3HTR2AHRH1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5497 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. | 2024-09-12 | — | — | US | claimed |
| US-12004868-B2 | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel | SIGNPATH PHARMA INC. (US) | 2024-06-11 | — | — | US | claimed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| US-20230381161-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | The George Institute for Global Health (AU) | 2023-11-30 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-4244341-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | Akttyva Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| US-20230233483-A1 | COMPOUND AND METHOD FOR THE TREATMENT OF CORONAVIRUSES | APTEEUS (FR) | 2023-07-27 | — | — | US | claimed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | claimed |
| US-20230125076-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | The George Institute for Global Health (AU) | 2023-04-27 | — | — | US | claimed |
| WO-1988004553-A1 | TREATMENT OF CARDIOVASCULAR AND CEREBRAL TOXICITY USING CALCIUM MODULATORS | NAHAS GABRIEL GEORGES (US) | 1988-06-30 | — | — | WO | claimed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| EP-0188595-A1 | A DRUG KIT OR DRUG COMPOSITION FOR USE IN PREVENTING AND TREATING ISCHAEMIC CELL DAMAGE AND PREPARATION THEREOF | PHARMACIA AKTIEBOLAG (SE) | 1986-07-30 | — | — | EP | claimed |
| US-4584294-A | Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents | MERCK & CO., INC. (US) | 1986-04-22 | — | — | US | claimed |
| WO-1986000812-A1 | A DRUG KIT OR DRUG COMPOSITION FOR USE IN PREVENTING AND TREATING ISCHAEMIC CELL DAMAGE AND PREPARATION THEREOF | PHARMACIA AB (SE) | 1986-02-13 | — | — | WO | claimed |
| EP-0166353-A2 | Benzofused lactams useful as antihypertensive agents and as cholecystokinin antagonists | MERCK & CO. INC. (US) | 1986-01-02 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| US-4500530-A | ADMINISTERING LIDOFLAZINE, FLUNARIZINE OR CINNARIZINE | RHEOTECH LABS, INC. | 1985-02-19 | — | — | US | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |